More problems for Hunter, James and Joe, page-3

First 3 Last

Share
Profile

Follow
hersuit

17,201 Posts.

112

06/06/24

14:27

Post #: 74195827
Share

Originally posted by thecurious1: ↑

Not all bad news.

Jesse noted that @hersuit's favourite legal expert Johnathan Turley thinks the jury might have been nullified by the presence of too many of The Blacks and Jurors with past drug issues.

"JESSE WATTERS: This might seem like an open-and-shut case, but Jonathan Turley points out that Hunter's legal team might have an ace up their sleeve.

It's called jury nullification.

It's when you pick a jury that will give you a not guilty verdict. They know you're guilty, but they just disagree with the law.

The strategy plays on the racial makeup of the jury, which is mostly black, as well as the Biden's influence in Delaware."

"WATTERS: All right Susan, let's go through some of these jurors.

Almost all of them seem to have some drug history or family history with drugs. One juror's childhood best friend died from a heroin overdose. Another juror had an alcoholic brother-in-law. Brother-in-law is now dead.

One juror's dad was shot dead and his brother was arrested for narcotics possession.
Another juror pled guilty to a DUI. And another juror had an older brother addicted to PCP and heroin."

Jesse Watters Attacks Black Jurors Serving On Hunter Biden Trial | Crooks and Liars

Expand

That and the jury and setting is in Bidens home town

Note how they and you are likely twisting JW's views
I watched JW and saw this and cant recall he discussed their families exposure to drugs etc and tragedy and mentioned their color
Much less that he "attacked the blacks"
Dishonest as usual
2 Upvote

Reply

Top Stories

ATH

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability

NWC

New World Resources inks complete PFS for Antler Copper Project in Arizona, USA

LRL

Labyrinth shares rocket by 219% on news of Comet Vale and Vivien gold project acquisitions

AI stocks: What to expect in 2024-25

CTT

Cettire shares jump on FY24 revenue growth up 80% vs pcp – but stock still badly bruised